Breast Cancer Patients May Be Offered Chemo-Free Treatment
Posted on: Friday, 18 May 2007, 09:00 CDT
Hormone therapy drugs such as AstraZeneca's Zoladex may be as effective as traditional chemotherapy in pre-menopausal breast cancer patients, according to a study from Cancer Research UK.
Researchers for the cancer charity analyzed 16 trials involving LHRH agonists and found them to be as effective as conventional chemotherapy for many pre-menopausal breast cancer patients with the added benefit of them being better tolerated by patients. About two thirds of pre-menopausal patients have hormone sensitive breast cancer which equates to around 5,500 women being diagnosed in the UK every year.
This means women, whose breast cancer is hormone sensitive, may not need risk becoming permanently infertile or suffering the unpleasant side effects caused by chemotherapy. LHRH agonists stop the pituitary gland producing luteinising hormone, and so remove the stimulus for the ovaries to make oestrogen. But once the treatment stops the ovarian function usually returns to normal.
Overall 42,000 women are diagnosed with breast cancer every year in the UK. Of these around 80 per cent are over the age of 50.
Kate Law, head of clinical trials at Cancer Research UK, said: "This is a very encouraging finding and suggests breast cancer treatment for some pre-menopausal women could be less devastating while being equally effective as conventional chemotherapy."
Source: Datamonitor
Related Articles
- Methadone Frequently Causes Menopausal Symptoms in Young Women
- Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
- Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
- European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) With Chemotherapy in Hormone Refractory Prostate Cancer Patients
- Breast Cancer Decline Tied to Decrease in HRT: Menopause & Living Well With Non-Hormonal Solutions
- St. Louis Cancer & Breast Institute Physician Says Hormone Replacement Therapy Does Indeed Create Breast Cancer Risk
- Highmark Foundation Awards Grants to Support Cancer, Avian Flu and Patient Care Programs
- Cell Genesys Announces Publication of Encouraging Phase 1/2 Clinical Results For GVAX(R) Immunotherapy for Prostate Cancer in Early Stage Patients Before Receiving Hormone Therapy
- New Cancer Center Clinic Targets High-Risk Women
- Report: Prostate Cancer, Breast Cancer Leading Newly Diagnosed Cancers
 |
 |
User Comments (0)
RSS Feeds